Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanzalintinib - Exelixis

Next Previous
Drug Profile

Zanzalintinib - Exelixis

Alternative Names: XL-092

Latest Information Update: 22 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; TYRO3 receptor protein tyrosine kinase antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Renal cell carcinoma
  • Phase II/III Neuroendocrine tumours; Squamous cell cancer
  • Phase II Liver cancer; Prostate cancer; Thyroid cancer
  • Phase I/II Germ cell cancer
  • Phase I Leiomyosarcoma; Liposarcoma; Solid tumours; Uterine cancer

Most Recent Events

  • 16 Dec 2025 Exelixis plans a phase II trial for Soft tissue sarcoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (PO) in June 2026 (NCT07283731)
  • 09 Dec 2025 Phase-II clinical trials in Neuroendocrine tumours (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06926634)
  • 12 Nov 2025 Merck Sharp & Dohme plans a phase III LITESPARK-033 trial for Renal cell carcinoma (Inoperable/Unresectable, Combination therapy, Late-stage disease, Second-line therapy or greater) in December 2025 (PO) (NCT07227402) (EudraCT2024-517136-21)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top